Abbott stock rebounded Wednesday after a “middling” quarter but was driven higher by its strong sales outlook and positive fourth-quarter performance in diabetes devices. The company expects 7-8% organic sales growth for the year, outperforming estimates, on top of record earnings per share. Sales of Abbott’s medical devices, including a significant boost in its diabetes division, fueled the gains. Shares rose nearly 1% to 117.80.
Source: https://www.investors.com/news/technology/abbott-stock-abbott-laboratories-q4-2024-earnings